POC Treatment in NTD

POC diagnostics delivers rapid information for patient care. The common platform is the lateral flow immunoassay. Recently, emerging molecular diagnostics have met requirements for speed, low cost, and ease of use for POC applications. A major driver for POC development is the ability to diagnose infectious diseases at sites with a limited infrastructure. The potential use in both wealthy and resource-limited settings has fuelled an intense effort to build on existing technologies and to generate new technologies for the diagnosis of a broad spectrum of infectious diseases. POC diagnostics also reduce the reliance on presumptive treatment and thereby facilitate antibiotic control. Rapid diagnostic tests work by detecting analyte that are found in or extracted from clinical samples. There are two primary types of analytes: microbial antigens and patient antibodies that are specific for microbial antigens.  However, there are emerging molecular technologies that enable nucleic acid-based approaches at the POC

  • Diagnostic Innovation
  • Antimicrobial Resistance
  • Mass Drug Administration
  • NTD Drugs
  • NTD Vector Control Agents
  • Disease-Specific Diagnostic Tools
  • Personalized POC Testing

Related Conference of POC Treatment in NTD

May 10-11, 2021

4th Global Experts Meeting on Infectious Diseases

Singapore City, Singapore
May 27-28, 2021

7th Rare Diseases and Orphan Drugs

Vienna, Austria
July 19-20, 2021

13th Global Infections Conference

Tokyo, Japan
September 06-07, 2021

11th World Congress on Rare Diseases and Orphan Drugs

Berlin, Germany
October 21-22, 2021

International Conference on Tropical Diseases and Cure

Zurich, Switzerland
November 22-23, 2021

3rd World Congress on Advancements in Tuberculosis and Lung Diseases

Singapore City, Singapore
February 07-08, 2022

9th International Congress on Infectious Diseases

Aberdeen, UK

POC Treatment in NTD Conference Speakers

Recommended Sessions

Related Journals

Are you interested in